Oncology

NICE recommends rituximab for the first line treatment of follicular lymphoma

NICE has today issued guidance to the NHS in England in Wales recommending rituximab as an option for the treatment of patients with symptomatic stage III and IV follicular lymphoma who have previously been untreated.
Read more

 http://www.nice.org.uk/page.aspx?o=367873...

National Institute for Health and Clinical Excellence